BLUE BELL, Pa., March 2, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it achieved compelling results in a study of its DNA vaccine for foot-and-mouth disease administered by Inovio's proprietary vaccine delivery technology. The preclinical data was highlighted by Dr. Niranjan Y. Sardesai, Inovio's Sr. VP of Research and Development, at the Vaccine World Summit being held in New Delhi, India, March 1–3. The presentation, entitled "Electroporation Mediated Delivery of DNA Vaccines: Translating the Promise to Prophylactic Vaccination," focused on Inovio's recent developments to advance novel vaccines for several emerging pathogens, including foot-and-mouth disease (FMD), Chikungunya, and dengue viruses.
The FMD virus is one of the most infectious diseases affecting farm animals including cattle, swine, sheep and goats, and is a serious threat to global food safety. Once an area is exposed to FMD, livestock & dairy exports are ceased and herds are culled. For example, in a major FMD outbreak in the UK in 2001, more than 4 million animals were slaughtered, resulting in more than $10 billion (USD) in economic losses. In a current FMD epidemic in South Korea, more than 3.3 million animals, mostly swine, have been culled in an attempt to keep the disease from spreading.
Because FMD can spread rapidly and beyond regional boundaries there is a need to develop vaccines that can simultaneously target different regional serotypes of FMD in a single vaccine. Inovio's SynCon™ technology enables rapid development of vaccines that can cover multiple serotypes simultaneously with a single formulation. Inovio, its subsidiary, VGX Animal Health (VAH), and its academic collaborators generated and tested SynCon™ DNA vac
|SOURCE Inovio Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved